In the AD group, A+T+ accounted for approximately 75% (range 70% [A1T3; 95% confidence interval, 55.8–85.3%] to 82.5% [A2T1; 95% confidence interval, 69.8–93.3%]); the difference from other groups was the lower prevalence of T+ obtained using CSF p-tau than tau PET in the case of A- (p > 0.05) (Figure 2D). Here, MAPT is linked to Alzheimer disease.